Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on B&M

(Sharecast News) - Analysts at Berenberg lowered their target price on discount retailer B&M from 630.0p to 590.0p on Monday as it noted a number of near-term catalysts lay ahead. Berenberg noted that B&M's share price has dropped roughly 55% since late 2023, with shares now at their early Covid-19 levels, despite consensus FY25 revenues and underlying earnings being 48% and 80% higher than pre-pandemic levels, respectively. It also noted B&M's shares have de-rated from a price-to-earnings ratio of around 15x to c8x.

The German bank, which has a 'buy' rating on the stock, said its new forecasts, with EBITDA reduced by 3-4% over FY25-27, reflect B&M's latest, slightly lowered, guidance. However, it pointed out that this still points to flat profit year-on-year, and free cash flow of over £300.0m per year - double the pre-Covid average - offering an 11% FCF yield and supporting a 10% total dividend yield.

"We expect share buybacks to be introduced in FY 2026E, driving double-digit-percentage EPS growth on a three-year view. Our DCF requires a long-term sales decline of circa 15% per year to derive the current share price, which makes no sense to us," said Berenberg.

As for future catalysts, Berenberg stated it expects B&M UK like-for-like sales in Q126 to inflect back into growth, helped by easier prior-year comparative periods, as well as some improvement in UK consumer demand, and the current run of favourable weather to be good for its gardening and outdoor categories.

"We expect B&M's market-leading value offer, as well as moderate price inflation across the sector, to continue to drive solid trading through FY26E. News on the group's new CEO hire (expected sooner rather than later) should also help to drive further interest in the shares. We see B&M facing minimal impacts from the latest tariff announcements," concluded Berenberg.

Reporting by Iain Gilbert at Sharescast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.